High circulating miR-185 levels in patients with dilated cardiomyopathy were associated with significantly lower cardiovascular mortality (0% vs 16.7%) and fewer heart failure re-hospitalizations compared to low miR-185 levels over a 1-year follow-up.
Cohort (n=91)
No
Are high circulating levels of miR-185 associated with improved clinical outcomes and cardiac function in patients with dilated cardiomyopathy?
High circulating levels of miR-185 are associated with improved cardiac function, reduced cardiovascular mortality, and fewer heart failure re-hospitalizations in patients with dilated cardiomyopathy.
Absolute Event Rate: 0% vs 16.7%
p-value: p=0.048
B cells contribute to the development of dilated cardiomyopathy (DCM) by inducing myocyte injuries and myocardial fibrosis. Our recent research indicated that microRNA (miR) -185 participated in human B-cell activation. Thus, this study was aimed to explore the relationship between miR-185 and DCM progression. Forty-one healthy volunteers and fifty newly diagnosed DCM patients were enrolled. The levels of plasma miR-185, TNF-α secreting B cells, and anti-heart autoantibody were detected. We found that the mean levels of plasma miR-185 in DCM patients were significantly higher than those in healthy controls. Furthermore, these DCM patients could be divided into miR-185(high) and miR-185(low) groups according to the cluster distribution. During one-year follow-up period, the miR-185(high) group showed apparent improvements in left ventricular ejection fraction, left ventricular end diastolic diameter, and NT-proBNP, accompanied by significant declines in both cardiovascular mortality and total admissions for heart failure re-hospitalizations. In addition, the levels of anti-β1-AR antibody and TNF-α secreting B cells were also reduced in miR-185(high) group. These findings suggested that high miR-185 levels might be associated with a favorable prognosis by repressing B cell function in DCM. The findings of this study need to be confirmed with larger sample size and longer duration of observation.
Yu et al. (Tue,) conducted a cohort in Dilated cardiomyopathy (n=91). High circulating miR-185 levels vs. Low circulating miR-185 levels was evaluated on Cardiovascular mortality at 12 months (p=0.048). High circulating miR-185 levels in patients with dilated cardiomyopathy were associated with significantly lower cardiovascular mortality (0% vs 16.7%) and fewer heart failure re-hospitalizations compared to low miR-185 levels over a 1-year follow-up.